These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34809621)

  • 1. Stabilization of UCA1 by N6-methyladenosine RNA methylation modification promotes colorectal cancer progression.
    He RZ; Jiang J; Hu X; Lei M; Li J; Luo W; Duan L; Hu Z; Mo YY; Luo DX; Peng WX
    Cancer Cell Int; 2021 Nov; 21(1):616. PubMed ID: 34809621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The m6A Reader IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression by Maintaining UCA1 Stability.
    Zhang D; Mai L; Zhang L; Huang G; Lin Z; Wang S; Rao G; Xie S; Pan C
    Recent Pat Anticancer Drug Discov; 2024 Aug; ():. PubMed ID: 39192648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
    Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
    Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-Methyladenosine Modification of PTTG3P Contributes to Colorectal Cancer Proliferation
    Zheng Y; Wang Y; Liu Y; Xie L; Ge J; Yu G; Zhao G
    Front Oncol; 2021; 11():669731. PubMed ID: 34660259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WTAP-mediated N6-methyladenine Modification of circEEF2 Promotes Lung Adenocarcinoma Tumorigenesis by Stabilizing CANT1 in an IGF2BP2-dependent Manner.
    Zheng H; Cao Z; Lv Y; Cai X
    Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38619801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
    Xiang S; Liang X; Yin S; Liu J; Xiang Z
    Am J Transl Res; 2020; 12(5):1789-1806. PubMed ID: 32509177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling.
    Liu X; He H; Zhang F; Hu X; Bi F; Li K; Yu H; Zhao Y; Teng X; Li J; Wang L; Zhang Y; Wu Q
    Cell Death Dis; 2022 May; 13(5):483. PubMed ID: 35595748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis.
    Peng WX; Liu F; Jiang JH; Yuan H; Zhang Z; Yang L; Mo YY
    Genes Dis; 2023 Mar; 10(2):554-567. PubMed ID: 37223505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2BP2 promotes pancreatic carcinoma progression by enhancing the stability of B3GNT6 mRNA via m6A methylation.
    Cao P; Wu Y; Sun D; Zhang W; Qiu J; Tang Z; Xue X; Qin L
    Cancer Med; 2023 Feb; 12(4):4405-4420. PubMed ID: 35908253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WTAP Mediated the N6-methyladenosine Modification of PDK4 to Regulate the Malignant Behaviors of Colorectal Cancer Cells
    Dai X; Chen K; Xie Y
    Curr Med Chem; 2023; 30(29):3368-3381. PubMed ID: 36154586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine modification, predicts poor prognosis and promotes growth and invasion in gliomas.
    Song T; Hu Z; Zeng C; Luo H; Liu J
    Heliyon; 2023 Jun; 9(6):e16280. PubMed ID: 37260902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development.
    Ye M; Chen J; Yu P; Hu C; Wang B; Bao J; Lu F; Zhong Y; Yan L; Kan J; Bai J; Tian Y; Tang Q
    FASEB J; 2023 Aug; 37(8):e23090. PubMed ID: 37428639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification.
    Hou P; Meng S; Li M; Lin T; Chu S; Li Z; Zheng J; Gu Y; Bai J
    J Exp Clin Cancer Res; 2021 Feb; 40(1):52. PubMed ID: 33526059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6.
    Zhao S; Zhang B; Yuan H; Yin Y; Qi S; Li W; Wu X; Yaling F
    Int J Biochem Cell Biol; 2022 Nov; 152():106296. PubMed ID: 36113831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.
    Ni WJ; Zhou H; Lu H; Ma NN; Hou BB; Li W; Kong FX; Yu JT; Hou R; Jin J; Wen JG; Zhang T; Meng XM
    Clin Transl Med; 2023 Aug; 13(8):e1359. PubMed ID: 37537731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader.
    Hu X; Peng WX; Zhou H; Jiang J; Zhou X; Huang D; Mo YY; Yang L
    Cell Death Differ; 2020 Jun; 27(6):1782-1794. PubMed ID: 31804607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.